Search Results - "Drooger, J.C."

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study by de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne-Marie C., van der Veldt, Astrid A.M., van Loenhout, C.J., van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, B.E.E.M., van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P., Libourel, E.J., Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C., Heller, R., de Groot, J.W.B., Stigt, J.A., Nuij, V.J.A.A., Pitz, C.C.M., Slingerland, M., Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C. van 't, Aarts, M.J.B., van Putten, J.W.G., Youssef, M., Cirkel, G.A., Herder, G.J.M., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H.T., Claessens, N.J.M., Faber, L.M., Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H., Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M., van Lindert, A.S.R., van de Wouw, A.J., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P.

“…Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse…”
Get full text

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study by van der Voort, Anna, Louis, Fleur M, van Ramshorst, Mette S, Kessels, Rob, Mandjes, Ingrid A, Kemper, Inge, Agterof, Mariette J, van der Steeg, Wim A, Heijns, Joan B, van Bekkum, Marlies L, Siemerink, Ester J, Kuijer, Philomeen M, Scholten, Astrid, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T F D, Mann, Ritse M, Sonke, Gabe S, van Leeuwen-Stok, E., van Leeuwen, L., de Graaf, H., van Riel, J.M.G.H., Houtsma, D., Vrijaldenhoven, S., van der Velden, A.W.G., Peerdeman, A.L., van den Brink - Schimmel, R.J., Drooger, J.C., Imholz, A.L.Th, Dercksen, M.W., Oulad Hadj, J., Bakker, S.D., van der Wouw, A.J., Kerver, E.D., Bouma, G., van Schaik, C., de Boer, M., Mandigers, C.M.P.W., Koornstra, R.H.T., Smals, A., Rietbroek, R.C., van der Padt - Pruijsten, A., den Boer, M.O., Bos, H., Schiphorst, P.P.J.B.M., Vriens, B.E.P.J., van Rossum, Q.C., Tol, J., Hoogwerf - Kluft, D., Kruijtzer - Schimmel, C.M.F., Oosterkamp, H.M., Baas, I.O., Dietvorst, A.H.P., Davidis - van Schoonhoven, M., van Dijk, M.A.

“…Patients with stage II–III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although…”
Get full text

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer by Buijs, S.M., Hoop, E. Oomen-de, Braal, C.L., van Rosmalen, M.M., Drooger, J.C., van Rossum-Schornagel, Q.C., Vastbinder, M.B., Koolen, S.L.W., Jager, A., Mathijssen, R.H.J.

“…Tamoxifen is important in the adjuvant treatment of hormone-sensitive breast cancer and substantially reduces recurrence; however, almost 50% of patients are…”
Get full text

ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics by Drooger, J C, Dees, A, Swaak, A J G

“…To compare the survival rate, and the clinical and laboratory characteristics in patients, characterized by the presence of certain anti-neutrophil cytoplasmic…”
Get full text